Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use
Open Access
- 25 February 2025
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 32 (3) , 128
Abstract
Advanced pancreatic cancer results in high morbidity and mortality. The standard of care treatment in the advanced setting changed in 2011 with the introduction of FOLFIRINOX (FFX) chemotherapy. However, it was highly toxic with significant risk of complications. We assessed the practice patterns of medical oncologists across Canada. Methods: We performed a retrospective study of consecutive patients with advanced pancreatic cancer treated with FFX at eight Canadian cancer centers. Demographic, treatment, and outcome data were collected and analyzed. Results: The median age of the patients was 61 (range 24–80), 43% were female, 96% had an ECOG PS of 0 or 1, and 50% had three or more metastatic sites. The median follow-up time was 20.8 months (95%CI 18.6–24.9). Physicians started FFX at the standard dose 31% of the time. Physicians prescribed GCSF for primary prophylaxis most when giving standard-dose FFX (30% of the time) in comparison to reduced dose with or without the 5-FU bolus. Dose reductions occurred in 78.1% of patients, while dose delay occurred in 65.2% of patients. Conclusions: Medical oncologists in Canada historically prescribed FFX to patients with advanced pancreatic cancer in a fashion that was not uniform, prior to the emergence of evidence for upfront dose reductions.Keywords
Funding Information
- Sanofi (OXALI_L_06150)
This publication has 32 references indexed in Scilit:
- Cell membrane biomimetic nanomedicines for cancer phototherapyInterdisciplinary Medicine, 2023
- Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic CancerClinical Colorectal Cancer, 2018
- A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancerCancer Chemotherapy and Pharmacology, 2018
- Uptake and Effectiveness of FOLFIRINOX for Advanced Pancreatic Cancer: a Population-based StudyClinical Oncology, 2018
- Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensityEuropean Journal of Cancer, 2017
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisThe Lancet Oncology, 2016
- A review of relative dose intensity and survival in patients with metastatic solid tumorsCritical Reviews in Oncology/Hematology, 2015
- Pancreatic cancer and FOLFIRINOX: a new era and new questionsCancer Medicine, 2015
- Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancerGynecologic Oncology, 2011
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996